You are here: Industry Insights > biosimilar

News List

GC pharma announces approval for Lantus biosimilar in Korea biospectrumasia
March 15, 2018
The company plans to launch Glarzia Prefilled Pen, a Lantus biosimilar developed by Indian drug maker Biocon, in the third quarter this year
UK launch for Europe’s first Herceptin biosimilar pharmatimes
March 09, 2018
MSD has launched in the UK Europe’s first biosimilar to Roche/Genentech’s Herceptin, providing an alternative option for treating early breast cancer, metastatic breast cancer and metastatic gastric cancer.
Ontruzant launches to become first Herceptin biosimilar available in the UK pharmafile
March 09, 2018
Ontruzant, the biosimilar version of Herceptin originally developed by Korean firm Samsung Bioepis, has launched for patients in the UK
DHA approves clinical trial application for JHL’s new biosimilar biospectrumasia
March 05, 2018
Dornase alfa is sold under the brand name Pulmozyme in the European Union (EU) and in the United States (US).
The Future Pattern of Biosimilars in China zhulikou431
March 02, 2018
The biosimilars in China have entered the fast lane of development, and CFDA is now open to and encouraging biosimilar R&D...
Mylan, Biocon receive CHMP opinion for Semglee, biosimilar insulin glargine expressbpd
January 30, 2018
Marketing applications for Semglee have been submitted in Australia, Canada, and the US and are planned for key emerging markets
Current Situation of Biosimilars in China I: A Focus on the Biosimilar Market in China Tang
December 11, 2017
According to the financial reports issued by global pharmaceutical giants in 2016, 7 biological drugs entered the list of global top 10 best-selling drugs.
Biocon pulls EU Herceptin biosim app but expects to return to the race next quarter fiercepharma
August 17, 2017
Biocon says it expects to finish plant fixes required by the European Medicines Agency by the end of August and will resubmit its application for a Herceptin biosimilar after that.
Biosimilar RENFLEXIS (infliximab) available on PBS from 1st August firstwordpharma
August 02, 2017
Potential for health budget savings with latest MSD biosimilar PBS listing;Infliximab biosimilar to be dispensed predominately through hospitals
Boehringer starts clinical study on interchangeability between adalimumab biosimilar candidate and U cphi-online
July 31, 2017
First study in the US to investigate an interchangeability designation for an adalimumab biosimilar candidate.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page